Trial reportNature cancer2024
Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
Trial report in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Miniature and versatile genome regulation TnpB-ωRNA toolkits facilitate cancer immunotherapy.Nature communications · 2026Article
- Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer.Translational andrology and urology · 2026Article
- Comparison of Neoadjuvant Chemotherapy, Chemoimmunotherapy, and Upfront Radical Cystectomy in High-Risk Bladder Cancer: A Single-Center Retrospective Study.Oncology research · 2026Article
- Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis.Frontiers in oncology · 2026Article
- piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization.Translational oncology · 2026Article
- Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.European urology open science · 2026Article
- Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.Frontiers in immunology · 2026Observational
- Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expression.Medical oncology (Northwood, London, England) · 2025Article
- Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.Journal of translational medicine · 2025Review
- Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.NPJ precision oncology · 2025Article
- Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study.Journal of translational medicine · 2025Article
- Artificial Intelligence-Assisted Urine Cytology for Noninvasive Detection of Muscle-Invasive Urothelial Carcinoma: A Multi-Center Diagnostic Study with Prospective Validation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Non-Invasive Tumor Budding Evaluation and Correlation with Treatment Response in Bladder Cancer: A Multi-Center Cohort Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer.Scientific reports · 2025Article
- Novel neoadjuvant therapies for muscle-invasive bladder cancer: Systematic review and meta-analysis.BJUI compass · 2025Review
- Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review.Current urology · 2025Review
- Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer.Frontiers in immunology · 2025Article
- Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Programmed death 1 blockade (tislelizumab) has been approved for metastatic urothelial carcinoma but not as part of neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). In this multicenter single-arm trial (ChiCTR2000037670), 65 participants with cT2-4aN0M0 MIBC received neoadjuvant gemcitabine-cisplatin plus tislelizumab; 57 of them underwent radical cystectomy (RC). The primary endpoint of pathologic complete response (pCR) rate was 50.9% (29/57, 95% confidence interval (CI) 37.3-64.4%) and the pathologic downstaging (secondary endpoint) rate was 75.4% (43/57, 95% CI 62.2-85.9%) in participants undergoing RC. Genomic and transcriptomic analyses revealed three MIBC molecular subtypes (S): S1 (immune-desert) with activated cell-cycle pathway, S2 (immune-excluded) with activated transforming growth factor-β pathway and S3 (immune-inflamed) with upregulated interferon-α and interferon-γ response. Post hoc analysis showed pCR rates of 16% (3/19, S1), 77% (10/13, S2) and 80% (12/15, S3) (P = 0.006). In conclusion, neoadjuvant gemcitabine-cisplatin plus tislelizumab for MIBC was compatible with an enhanced pCR rate.
Indexed as
Identifiers
39256488What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.